5-HT1 AND 5-HT2 BINDING-PROPERTIES OF DERIVATIVES OF THE HALLUCINOGEN 1-(2,5-DIMETHOXYPHENYL)-2-AMINOPROPANE(2,5-DMA)

被引:149
作者
SHANNON, M
BATTAGLIA, G
GLENNON, RA
TITELER, M
机构
[1] VIRGINIA POLYTECH INST & STATE UNIV, SCH PHARM, DEPT MED CHEM, BLACKSBURG, VA 24061 USA
[2] UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A1, ONTARIO, CANADA
关键词
D O I
10.1016/0014-2999(84)90333-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The affinities of a series of 1-(2.5-dimethoxyphenyl)-2-aminopropane (2.5-DMA) derivatives, most of which are hallucinogenic in man, and several related agents were determined for rat cortical serotonin (5-HT) binding sites. Competition assays were performed in which these agents were competed for the 5-HT2 binding of [3H]ketanserin, or the 5-HT1 binding of [3H]LSD (in the presence of ketanserin). The R(-)-isomers of DOI, DOM and DON (i.e., the 4-iodo, -methyl and -nitro derivatives of 2.5-DMA) were more potent than their racemates and demonstrated selectivity for 5-HT2 sites. These same agents in competing for [3H]ketanserin binding resulted in Hill coefficients significantly less than unity; computer-assisted analysis indicated a 2-state model better fir the data. In the presence of 10-4 M Gpp(NH)p [5''-guanylimidodiphosphate] the competition curve for R(-)-DOI produced a Hill coefficient close to unity. Apparently, certain derivatives of 2,5-DMA, in particular R(-)-DOI, may be potent and selective agonists at 5-HT2 binding sites, sites that may constitute a serotonin receptor regulated by a guanine nucleotide regulatory protein. The interactions of these agents at 5-HT1 sites was with a lower affinity and a lack of stereoselectivity. Although DOI and DOM are among the most potent of these agents as hallucinogens, it is still too premature to draw any conclusions regarding a possible relationship between 5-HT binding and hallucinogenic potency.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 10 条
[1]   MODULATION OF BRAIN S-2 SEROTONIN RECEPTORS BY LITHIUM, SODIUM AND KCL [J].
BATTAGLIA, G ;
SHANNON, M ;
TITELER, M .
LIFE SCIENCES, 1983, 32 (22) :2597-2601
[2]  
BATTAGLIA G, 1984, MOL PHARM
[3]   [H-3] MESULERGINE, A SELECTIVE LIGAND FOR SEROTONIN-2 RECEPTORS [J].
CLOSSE, A .
LIFE SCIENCES, 1983, 32 (21) :2485-2495
[4]   DRUG-INDUCED DISCRIMINATION - A DESCRIPTION OF THE PARADIGM AND A REVIEW OF ITS SPECIFIC APPLICATION TO THE STUDY OF HALLUCINOGENIC AGENTS [J].
GLENNON, RA ;
ROSECRANS, JA ;
YOUNG, R .
MEDICINAL RESEARCH REVIEWS, 1983, 3 (03) :289-340
[5]   BEHAVIORAL AND SEROTONIN RECEPTOR PROPERTIES OF 4-SUBSTITUTED DERIVATIVES OF THE HALLUCINOGEN 1-(2,5-DIMETHOXYPHENYL)-2-AMINOPROPANE [J].
GLENNON, RA ;
YOUNG, R ;
BENINGTON, F ;
MORIN, RD .
JOURNAL OF MEDICINAL CHEMISTRY, 1982, 25 (10) :1163-1168
[6]   INDOLEALKYLAMINE AND PHENALKYLAMINE HALLUCINOGENS - EFFECT OF ALPHA-METHYL AND N-METHYL SUBSTITUENTS ON BEHAVIORAL ACTIVITY [J].
GLENNON, RA ;
YOUNG, R ;
JACYNO, JM .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (07) :1267-1273
[7]   ANTAGONISM OF THE EFFECTS OF THE HALLUCINOGEN DOM AND THE PURPORTED 5-HT AGONIST QUIPAZINE BY 5-HT2 ANTAGONISTS [J].
GLENNON, RA ;
YOUNG, R ;
ROSECRANS, JA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 91 (2-3) :189-196
[8]  
LEYSEN JE, 1982, MOL PHARMACOL, V21, P301
[9]  
PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687
[10]  
SHULGIN AT, 1978, HDB PSYCHOPHARMACOLO, P231